SLN earnings analysis
What we found in SLN's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Silence Therapeutics reported $0 of second-quarter revenue and a $0.09 loss per share, but the net loss improved to $12.268 million from $27.354 million year over year as R&D expense fell by $8.4 million. The filing provides no quantitative EPS or revenue guidance and does not address the prior $22.0 million-$24.0 million full-year revenue outlook. Ongoing losses and the absence of quarterly revenue remain significant risks, although controls were assessed as effective as of June 30, 2026.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue remained at $0
- Second-quarter revenue was $0, while reported EPS was a loss of $0.09. No segment revenue breakdown was disclosed.
- Net loss narrowed materially
- Net loss narrowed to $12.268 million from $27.354 million in the prior-year period, an improvement of $15.086 million.
- R&D expense fell $8.4 million
- Research and development expense declined by $8.4 million year over year, contributing to the narrower net loss.
- Disclosure controls deemed effective
- Management concluded that disclosure controls and procedures were effective at the reasonable assurance level as of June 30, 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- No quarterly revenue
- Revenue was $0 in the quarter, underscoring the company’s dependence on future licensing, collaboration or product-related revenue to fund operations.
- Continuing operating losses
- The company continued to report a net loss of $12.268 million despite the year-over-year improvement from $27.354 million, indicating ongoing operating losses and financing needs.
- No new risk-factor disclosure
- The risk-factor section points investors back to the 2025 Form 10-K and does not identify new or changed risk factors; the filing also states that the company is party to 0 material legal proceedings at this time.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.09
What they said about what is next.
No numeric EPS guidance was provided. The prior full-year revenue outlook of $22.0 million-$24.0 million was not addressed in the filing/release.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 7, 2026
- Silence Therapeutics reported a first quarter 2026 net loss of $14.96 million, significantly improving from a loss of $28.53 million in the same period last year. Revenue from collaboration with AstraZeneca increased to…
- 10-K · March 5, 2026
- Silence Therapeutics (SLN) continues to focus on advancing its RNA-based therapy pipeline while facing significant operating losses. The company reported a dramatic decline in revenue for FY 2025, dropping to $0.6…
- 10-Q · November 6, 2025
- Silence Therapeutics PLC reported a significant decline in revenue for Q3 2025 with total revenue of $1.5 million, down from $1.3 million year-over-year. The company also saw a notable increase in operating loss, along…
- 10-Q · August 7, 2025
- Silence Therapeutics PLC reported significant declines in revenue and EPS for Q2 2025, with actual revenues of $224,000 compared to estimates of $5.43 million. Gross profit was deeply negative at $2.58 million,…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing SLN makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever